Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to measure the amount of study drug (BMS-986189) in the blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a single dose.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BMS-986189 | Experimental | Specified Dose on Specified Day |
|
| Placebo | Placebo Comparator | Specified Dose on Specified Day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986189 | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum observed concentration (Cmax) | Day 1 to Day 30 | |
| Time of maximum observed concentration (Tmax) | Day 1 to Day 30 | |
| Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(O-T)) | Day 1 to Day 30 | |
| Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) | Day 1 to Day 30 | |
| Half Life (T-HALF) | Day 1 to Day 30 | |
| Total Body Clearance (CLT/F) | Day 1 to Day 30 | |
| Apparent volume of distribution at steady state (Vss/F) | Day 1 to Day 30 | |
| Deaths leading to discontinuation | Day 1 to Day 30 | |
| Adverse events (AEs) leading to discontinuation | Day 1 to Day 30 | |
| Serious adverse events (SAEs) leading to discontinuation | Day 1 to Day 30 | |
| Lab abnormalities leading to discontinuation |
Not provided
Not provided
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Covance Clinical Research Unit, Inc. | Evansville | Indiana | 47710 | United States |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Patient Recruiting | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Day 1 to Day 30 |
| D013568 |
| Pathological Conditions, Signs and Symptoms |